HomeCompareMLLCF vs STAG

MLLCF vs STAG: Dividend Comparison 2026

MLLCF yields 40.32% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLLCF wins by $217.6K in total portfolio value
10 years
MLLCF
MLLCF
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.0K
Annual income
$40,141.97
Full MLLCF calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — MLLCF vs STAG

📍 MLLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLLCFSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLLCF + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLLCF pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLLCF
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$34,120.67/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, MLLCF beats the other by $33,727.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLLCF + STAG for your $10,000?

MLLCF: 50%STAG: 50%
100% STAG50/50100% MLLCF
Portfolio after 10yr
$127.2K
Annual income
$20,302.09/yr
Blended yield
15.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

MLLCF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
1/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLLCF buys
0
STAG buys
0
No recent congressional trades found for MLLCF or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLLCFSTAG
Forward yield40.32%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$236.0K$18.3K
Annual income after 10y$40,141.97$462.22
Total dividends collected$178.0K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: MLLCF vs STAG ($10,000, DRIP)

YearMLLCF PortfolioMLLCF Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$14,732$4,032.26$10,665$345.09+$4.1KMLLCF
2$21,315$5,551.80$11,364$357.70+$10.0KMLLCF
3$30,314$7,507.11$12,098$370.43+$18.2KMLLCF
4$42,415$9,978.09$12,869$383.28+$29.5KMLLCF
5$58,431$13,047.54$13,677$396.23+$44.8KMLLCF
6$79,320$16,798.63$14,524$409.27+$64.8KMLLCF
7$106,185$21,312.20$15,411$422.41+$90.8KMLLCF
8$140,281$26,663.87$16,339$435.61+$123.9KMLLCF
9$183,022$32,921.38$17,311$448.89+$165.7KMLLCF
10$235,976$40,141.97$18,327$462.22+$217.6KMLLCF

MLLCF vs STAG: Complete Analysis 2026

MLLCFStock

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Full MLLCF Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this MLLCF vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLLCF vs SCHDMLLCF vs JEPIMLLCF vs OMLLCF vs KOMLLCF vs MAINMLLCF vs PLDMLLCF vs EQRMLLCF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.